0001493152-26-022628
SEC filingOperating losses narrowed significantly year-over-year due to disciplined cost management amid strategic pivot to cannabinoid therapeutics, though cash burn and low liquidity highlight pre-revenue development challenges.
The Company strategically shifted focus from its initial cannabis patch product, which achieved limited orders, to licensing SZS's novel cannabinoid therapeutic. This license targets treatment of autism, schizophrenia, Parkinson's disease, Alzheimer's, and other neuropsychiatric disorders. Management elected this pivot believing it offers greater potential for growth and profitability, with plans to develop the therapeutic further through clinical studies to substantiate safety and efficacy, beginning in neuropsychiatric disorders.
Net income loss improved dramatically by 86.2% to -$33.4K from -$242.4K year-over-year, aligning with the operating loss trend. Diluted EPS remained at $0.00, consistent with the prior period. The narrower loss stems from lower operating expenses and elimination of larger prior-year charges, positioning the Company with reduced bottom-line pressure amid its pre-revenue stage.